The particulars: 95.2% · PeptideDetective · 98.8% · Janoshik.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
95.2 and 98.8 are 3.6 percentage points apart, which sounds small until you restate it as impurity. PeptideDetective is leaving 4.8 per cent of the detected area unassigned and Janoshik 1.2 per cent — a factor of 4 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 95.2 and 98.8 are two measurements of slightly different quantities that happen to share a unit.
Mechanically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
The part that matters: integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 6 Nov 2024 by mz_4113 — added the placebo-arm figures
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemRead the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
It helps to be literal here: tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Specifically, the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
Compare purity within a single laboratory on the same method, never across laboratories.
Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask Peptide is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.